|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
TWI343377B
(en)
*
|
2002-03-13 |
2011-06-11 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US20060084682A1
(en)
*
|
2002-12-13 |
2006-04-20 |
Heerding Dirk A |
Thrombopoietin mimetics
|
|
ATE429250T1
(de)
*
|
2003-02-26 |
2009-05-15 |
Kowa Co |
Mittel zur behandlung der allergischen kontaktdermatitis
|
|
BRPI0412851A
(pt)
|
2003-07-24 |
2006-10-03 |
Warner Lambert Co |
benzamidazóis de n-metila-substituìdos
|
|
US7538120B2
(en)
*
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
KR101127201B1
(ko)
|
2003-09-22 |
2012-04-12 |
에스*바이오 피티이 리미티드 |
벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
|
|
US7517994B2
(en)
*
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
NZ547481A
(en)
|
2003-11-19 |
2009-12-24 |
Array Biopharma Inc |
Heterocyclic inhibitors of mek and methods of use thereof
|
|
US7732616B2
(en)
*
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
US20050130954A1
(en)
*
|
2003-11-21 |
2005-06-16 |
Mitchell Ian S. |
AKT protein kinase inhibitors
|
|
JP2007513967A
(ja)
*
|
2003-12-11 |
2007-05-31 |
セラヴァンス， インコーポレーテッド |
変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
|
|
AR051248A1
(es)
|
2004-10-20 |
2007-01-03 |
Applied Research Systems |
Derivados de 3-arilamino piridina
|
|
ATE443063T1
(de)
*
|
2004-12-01 |
2009-10-15 |
Merck Serono Sa |
Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
|
|
US7429667B2
(en)
*
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
CN102898364A
(zh)
|
2005-05-18 |
2013-01-30 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
EP1904061B1
(en)
*
|
2005-06-23 |
2018-12-26 |
Array Biopharma, Inc. |
SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
|
|
CN101248060B
(zh)
*
|
2005-06-23 |
2014-09-10 |
阵列生物制药公司 |
用于制备苯并咪唑化合物的方法
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
AU2012261703B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
CN103524392B
(zh)
*
|
2005-10-07 |
2018-06-01 |
埃克塞利希斯股份有限公司 |
作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
|
|
AU2013203939B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
US7572460B2
(en)
*
|
2005-10-25 |
2009-08-11 |
Rodrigo Rodriguez-Kabana |
Hydrogen cyanamide pesticide formulations
|
|
US7968108B2
(en)
*
|
2005-10-25 |
2011-06-28 |
Metbro Distributing L.P. |
Hydrogen cyanamide pesticide formulations
|
|
EP1966155A1
(en)
*
|
2005-12-21 |
2008-09-10 |
AstraZeneca AB |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
RU2418790C3
(ru)
*
|
2005-12-21 |
2022-03-14 |
Астразенека Аб |
Новая гидросульфатная соль
|
|
TWI405756B
(zh)
*
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
|
CA2534243A1
(fr)
|
2006-01-25 |
2007-07-25 |
Hydro Quebec |
Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
WO2007121269A2
(en)
|
2006-04-11 |
2007-10-25 |
Ardea Biosciences, Inc. |
N-aryl-n'alkyl sulfamides as mek inhibitors
|
|
ES2354182T3
(es)
*
|
2006-04-18 |
2011-03-10 |
Ardea Biosciences, Inc. |
Piridona sulfonamidas y piridona sulfamidas como inhibidores de mek.
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
CN101511842B
(zh)
|
2006-07-06 |
2012-10-31 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
|
|
US8063050B2
(en)
*
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
WO2008006032A1
(en)
*
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
|
US8492378B2
(en)
*
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
|
WO2008024725A1
(en)
*
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
|
CN101583616B
(zh)
*
|
2006-08-21 |
2012-05-30 |
健泰科生物技术公司 |
氮杂苯并噻吩基化合物及使用方法
|
|
EP2069359B1
(en)
|
2006-08-21 |
2014-11-12 |
Genentech, Inc. |
Aza-benzothiophenyl compounds and methods of use
|
|
ES2703723T3
(es)
|
2006-12-14 |
2019-03-12 |
Exelixis Inc |
Métodos para usar inhibidores de MEK
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
US20100130519A1
(en)
*
|
2007-04-13 |
2010-05-27 |
Stephen Robert Wedge |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
|
US8509487B2
(en)
*
|
2007-04-19 |
2013-08-13 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
System and method for optically measuring a parameter of an object
|
|
WO2008157179A2
(en)
|
2007-06-12 |
2008-12-24 |
Genentech, Inc. |
N-substituted azaindoles and methods of use
|
|
US8618097B2
(en)
|
2007-07-05 |
2013-12-31 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
SI2173723T1
(sl)
*
|
2007-07-05 |
2011-12-30 |
Array Biopharma Inc |
Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
KR20100089082A
(ko)
*
|
2007-10-15 |
2010-08-11 |
아스트라제네카 아베 |
조합 059
|
|
US8022057B2
(en)
|
2007-11-12 |
2011-09-20 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
PE20131210A1
(es)
|
2007-12-19 |
2013-10-31 |
Genentech Inc |
Derivados de 5-anilinoimidazopiridina como inhibidores de mek
|
|
CA2704125A1
(en)
|
2007-12-19 |
2009-07-09 |
Genentech, Inc. |
8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
|
|
WO2009080523A1
(en)
|
2007-12-20 |
2009-07-02 |
F. Hoffmann-La Roche Ag |
Substituted hydantoins as mek kinase inhibitors
|
|
ES2387707T3
(es)
|
2007-12-21 |
2012-09-28 |
Genentech, Inc. |
Azaindolizinas y procedimientos de uso
|
|
EP2240455B1
(en)
*
|
2008-01-09 |
2012-12-26 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
|
JP5346345B2
(ja)
*
|
2008-01-09 |
2013-11-20 |
アレイ バイオファーマ、インコーポレイテッド |
Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
|
|
EP2240494B1
(en)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Thieno-pyridine derivatives as mek inhibitors
|
|
SA109300195B1
(ar)
|
2008-03-28 |
2013-04-20 |
Astrazeneca Ab |
تركيبة صيدلانية جديدة مضادة للسرطان
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2009157167A1
(ja)
|
2008-06-23 |
2009-12-30 |
パナソニック株式会社 |
無線通信基地局装置および参照信号割当方法
|
|
WO2010003025A1
(en)
|
2008-07-01 |
2010-01-07 |
Genentech, Inc. |
Bicyclic heterocycles as mek kinase inhibitors
|
|
JP5615274B2
(ja)
*
|
2008-07-01 |
2014-10-29 |
ジェネンテック， インコーポレイテッド |
Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
|
|
SI2307376T1
(sl)
|
2008-08-04 |
2016-02-29 |
Merck Patent Gmbh |
Nove spojine fenilamino izonikotinamida
|
|
CN101653607B
(zh)
*
|
2008-08-19 |
2013-02-13 |
鼎泓国际投资（香港）有限公司 |
含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
|
|
EP2358202B1
(en)
*
|
2008-11-03 |
2016-06-15 |
Merck Sharp & Dohme Corp. |
Benzimidazole and aza-benzimidazole carboxamides
|
|
EP2346818B1
(en)
|
2008-11-10 |
2012-12-05 |
Bayer Intellectual Property GmbH |
Substituted sulphonamido phenoxybenzamides
|
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011047796A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
EP2491016A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
|
KR20130048293A
(ko)
|
2010-06-25 |
2013-05-09 |
노파르티스 아게 |
단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
|
|
ES2575995T3
(es)
|
2010-08-05 |
2016-07-04 |
Case Western Reserve University |
Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
|
|
ES2616238T3
(es)
|
2010-10-06 |
2017-06-12 |
Glaxosmithkline Llc, Corporation Service Company |
Derivados de bencimidazol como inhibidores de PI3 quinasa
|
|
CA2816188A1
(en)
|
2010-10-29 |
2012-05-03 |
Marion Hitchcock |
Substituted phenoxypyridines
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
AU2011349446C1
(en)
|
2010-12-22 |
2016-01-21 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
|
US8815853B2
(en)
|
2010-12-23 |
2014-08-26 |
Sanofi |
Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
|
|
KR20140022053A
(ko)
|
2011-04-01 |
2014-02-21 |
제넨테크, 인크. |
Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
|
|
ES2620644T3
(es)
|
2011-04-01 |
2017-06-29 |
Genentech, Inc. |
Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
|
|
WO2012145503A1
(en)
|
2011-04-21 |
2012-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
US20140228418A1
(en)
*
|
2011-05-23 |
2014-08-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
|
CA2836364C
(en)
|
2011-05-25 |
2021-01-26 |
Universite Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
EP2739358B1
(en)
|
2011-08-01 |
2018-11-28 |
F.Hoffmann-La Roche Ag |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
US10813630B2
(en)
|
2011-08-09 |
2020-10-27 |
Corquest Medical, Inc. |
Closure system for atrial wall
|
|
US10314594B2
(en)
|
2012-12-14 |
2019-06-11 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
US10307167B2
(en)
|
2012-12-14 |
2019-06-04 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
CA2846454A1
(en)
|
2011-08-31 |
2013-05-10 |
Novartis Ag |
Synergistic combinations of pi3k- and mek-inhibitors
|
|
RU2014112324A
(ru)
|
2011-09-01 |
2015-10-10 |
Новартис Аг |
Применение органического соединения для лечения синдрома нунан
|
|
EP2570127A1
(en)
|
2011-09-16 |
2013-03-20 |
Sanofi |
Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
|
|
RU2629116C2
(ru)
|
2011-10-14 |
2017-08-24 |
Эррэй Биофарма Инк. |
Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
|
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とｈｓｐ９０阻害剤の組合せ療法
|
|
WO2013067162A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
EP2780010A1
(en)
|
2011-11-14 |
2014-09-24 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
|
MX350957B
(es)
|
2011-11-23 |
2017-09-27 |
Medimmune Llc |
Moleculas de union especificas para her3 y usos de las mismas.
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
EP2802658A2
(en)
|
2012-01-09 |
2014-11-19 |
Novartis AG |
Rnai agents to treat beta-catenin related diseases
|
|
WO2013109142A1
(en)
|
2012-01-16 |
2013-07-25 |
Stichting Het Nederlands Kanker Instituut |
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
CN103204822B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
AU2013235596B9
(en)
*
|
2012-03-20 |
2017-12-14 |
Amgen Inc. |
Combination therapy of a MEK inhibitor and IGF1R inhibitor
|
|
US10054835B2
(en)
|
2012-04-09 |
2018-08-21 |
Switch Materials, Inc. |
Switching materials, and compositions and methods for making same
|
|
US9588358B2
(en)
|
2012-05-29 |
2017-03-07 |
Switch Materials, Inc. |
Optical filter comprising a variable transmittance layer
|
|
KR20150013332A
(ko)
|
2012-05-31 |
2015-02-04 |
바이엘 파마 악티엔게젤샤프트 |
간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
JP6335169B2
(ja)
|
2012-08-17 |
2018-05-30 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
|
|
BR112015007083A2
(pt)
|
2012-10-02 |
2017-07-04 |
Epitherapeutics Aps |
inibidores de histona demetilases
|
|
HRP20180670T1
(hr)
|
2012-10-12 |
2018-07-13 |
Exelixis Inc. |
Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
|
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
|
PL3702351T3
(pl)
*
|
2012-10-19 |
2024-04-02 |
Array Biopharma, Inc. |
Formulacja zawierająca inhibitor mek
|
|
US20140142689A1
(en)
|
2012-11-21 |
2014-05-22 |
Didier De Canniere |
Device and method of treating heart valve malfunction
|
|
US9446043B2
(en)
|
2012-11-29 |
2016-09-20 |
Novartis Ag |
Pharmaceutical combinations
|
|
WO2014097125A1
(en)
|
2012-12-20 |
2014-06-26 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
CN105229144A
(zh)
|
2013-02-22 |
2016-01-06 |
细胞动力学国际有限公司 |
通过组合的遗传工程和化学工程经由正向编程产生肝细胞
|
|
WO2014133071A1
(ja)
|
2013-02-27 |
2014-09-04 |
第一三共株式会社 |
Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
|
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
|
JP6433974B2
(ja)
|
2013-03-14 |
2018-12-05 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
|
|
DK2976106T3
(da)
*
|
2013-03-21 |
2021-06-14 |
Array Biopharma Inc |
Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
|
|
AR097617A1
(es)
|
2013-09-13 |
2016-04-06 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos del 2h-indazol
|
|
EP3046557A1
(en)
|
2013-09-20 |
2016-07-27 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US9566443B2
(en)
|
2013-11-26 |
2017-02-14 |
Corquest Medical, Inc. |
System for treating heart valve malfunction including mitral regurgitation
|
|
JP6407288B2
(ja)
|
2013-12-19 |
2018-10-17 |
イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ |
抗菌性１ｈ−インダゾール及び１ｈ−インドール誘導体
|
|
AU2015206603B9
(en)
|
2014-01-14 |
2019-07-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
AU2015210750B2
(en)
|
2014-01-31 |
2020-08-20 |
Children's Medical Center Corporation |
Antibody molecules to TIM-3 and uses thereof
|
|
SG11201606934SA
(en)
|
2014-03-04 |
2016-09-29 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
AR099612A1
(es)
|
2014-03-04 |
2016-08-03 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3126345A1
(en)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
|
WO2015164228A1
(en)
|
2014-04-21 |
2015-10-29 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
EP3143007B1
(en)
|
2014-05-16 |
2018-07-11 |
Idorsia Pharmaceuticals Ltd |
Antibacterial quinazoline-4(3h)-one derivatives
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
MX2017000546A
(es)
|
2014-07-15 |
2017-03-08 |
Genentech Inc |
Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
|
|
EA201790154A1
(ru)
|
2014-08-27 |
2017-08-31 |
Джилид Сайэнс, Инк. |
Соединения и способы для ингибирования гистоновых деметилаз
|
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
WO2016061142A1
(en)
|
2014-10-14 |
2016-04-21 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
US10842626B2
(en)
|
2014-12-09 |
2020-11-24 |
Didier De Canniere |
Intracardiac device to correct mitral regurgitation
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
CN107108637B
(zh)
|
2014-12-23 |
2019-10-29 |
诺华股份有限公司 |
三唑并嘧啶化合物及其用途
|
|
WO2016123100A1
(en)
|
2015-01-26 |
2016-08-04 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CN105566225A
(zh)
*
|
2015-02-16 |
2016-05-11 |
苏州晶云药物科技有限公司 |
一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
JO3746B1
(ar)
|
2015-03-10 |
2021-01-31 |
Aduro Biotech Inc |
تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
|
|
CA2976766A1
(en)
|
2015-03-25 |
2016-09-29 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
EP4378957A3
(en)
|
2015-07-29 |
2024-08-07 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
AR105646A1
(es)
|
2015-08-11 |
2017-10-25 |
Actelion Pharmaceuticals Ltd |
Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
|
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
|
WO2017037579A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Mdm2 inhibitors and combinations thereof
|
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
|
CA3001917A1
(en)
|
2015-10-16 |
2017-04-20 |
Fate Therapeutics, Inc. |
Platform for the induction & maintenance of ground state pluripotency
|
|
KR20250099459A
(ko)
|
2015-11-03 |
2025-07-01 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 그의 용도
|
|
CN108368520B
(zh)
|
2015-11-04 |
2023-01-17 |
菲特治疗公司 |
多能细胞的基因组工程改造
|
|
WO2017078807A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
SG11201805186VA
(en)
|
2016-01-20 |
2018-07-30 |
Fate Therapeutics Inc |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
EP3424505A4
(en)
|
2016-03-04 |
2019-10-16 |
Taiho Pharmaceutical Co., Ltd. |
PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
BR112018074941A2
(pt)
|
2016-06-03 |
2019-03-12 |
Caponigro Giordano |
combinações farmacêuticas
|
|
WO2017221092A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
IL263429B
(en)
|
2016-06-20 |
2022-08-01 |
Novartis Ag |
Crystalline forms of triazolopyrimidine compound
|
|
US10676479B2
(en)
|
2016-06-20 |
2020-06-09 |
Novartis Ag |
Imidazolepyridine compounds and uses thereof
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
WO2018065924A1
(en)
*
|
2016-10-04 |
2018-04-12 |
Sun Pharmaceutical Industries Limited |
Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
CN108084078B
(zh)
*
|
2016-11-24 |
2021-07-30 |
中山大学 |
一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
|
|
JP7098615B2
(ja)
|
2016-12-05 |
2022-07-11 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
EP3372624A1
(en)
|
2017-03-06 |
2018-09-12 |
Henkel AG & Co. KGaA |
One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
CN111646946A
(zh)
*
|
2017-11-14 |
2020-09-11 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的苯并咪唑化合物及包含该化合物的组合物
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
EP4470621A3
(en)
|
2018-03-19 |
2025-05-07 |
Taiho Pharmaceutical Co., Ltd. |
Use of sodium alkyl sulfate
|
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
|
MA52777A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Agents de liaison psma et utilisations correspondantes
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
PT4541381T
(pt)
|
2018-07-25 |
2026-03-17 |
Advanced Accelerator Applications S A |
Soluções estáveis e concentradas de complexos de radionuclídeos
|
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
EP3837256B1
(en)
|
2018-08-17 |
2023-03-08 |
Novartis AG |
Urea compounds and compositions as smarca2/brm-atpase inhibitors
|
|
CN112867512A
(zh)
|
2018-09-25 |
2021-05-28 |
意大利国际先进加速器应用有限公司 |
联合疗法
|
|
US12378240B2
(en)
|
2018-11-20 |
2025-08-05 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
JP7546297B2
(ja)
|
2018-11-20 |
2024-09-06 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのチエニル－アニリン化合物
|
|
MA55141A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés cyanoaryl-aniline pour le traitement d'affections de la peau
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CA3124330A1
(en)
|
2018-12-21 |
2020-06-25 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
AU2020221247B2
(en)
|
2019-02-12 |
2024-12-12 |
Sumitomo Pharma America, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
EP3942045A1
(en)
|
2019-03-21 |
2022-01-26 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020212832A1
(en)
*
|
2019-04-16 |
2020-10-22 |
Alembic Pharmaceuticals Limited |
Process of preparation of benzimidazole compounds
|
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
|
TWI817018B
(zh)
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
|
|
CA3150284A1
(en)
|
2019-09-26 |
2021-04-01 |
Novartis Ag |
Aza-quinoline compounds and uses thereof
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021116901A1
(en)
*
|
2019-12-09 |
2021-06-17 |
Biocon Limited |
Forms of binimetinib and process for preparation thereof
|
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
WO2021185291A1
(zh)
*
|
2020-03-17 |
2021-09-23 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
TW202200146A
(zh)
|
2020-04-10 |
2022-01-01 |
日商大鵬藥品工業股份有限公司 |
使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
|
|
AU2021289163B2
(en)
|
2020-06-09 |
2024-05-02 |
Array Biopharma Inc. |
4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4225307A1
(en)
|
2020-10-05 |
2023-08-16 |
Pierre Fabre Medicament |
Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
CN112759552A
(zh)
*
|
2020-12-31 |
2021-05-07 |
武汉九州钰民医药科技有限公司 |
司美替尼的合成方法
|
|
CN112679438A
(zh)
*
|
2020-12-31 |
2021-04-20 |
武汉九州钰民医药科技有限公司 |
制备司美替尼的方法
|
|
US12141240B2
(en)
|
2021-01-20 |
2024-11-12 |
Rutgers, The State University Of New Jersey |
Method of calibration using master calibration function
|
|
JP2024503893A
(ja)
*
|
2021-01-21 |
2024-01-29 |
エヌフレクション セラピューティクス インコーポレイテッド |
ピロロピリジン－アニリン化合物を調製するための方法
|
|
KR20230137393A
(ko)
|
2021-01-28 |
2023-10-04 |
얀센 바이오테크 인코포레이티드 |
Psma 결합 단백질 및 이의 용도
|
|
KR20230170644A
(ko)
|
2021-02-02 |
2023-12-19 |
르 라보레또레 쎄르비에르 |
선택적 bcl-xl protac 화합물 및 사용 방법
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
WO2022221586A1
(en)
*
|
2021-04-15 |
2022-10-20 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a pkc inhibitor and a mek inhibitor
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022251193A1
(en)
|
2021-05-27 |
2022-12-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CN117642166A
(zh)
|
2021-06-09 |
2024-03-01 |
中外制药株式会社 |
用于癌症治疗的组合疗法
|
|
WO2022262699A1
(zh)
*
|
2021-06-17 |
2022-12-22 |
深圳市塔吉瑞生物医药有限公司 |
取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
|
|
MX2024000313A
(es)
|
2021-07-09 |
2024-03-06 |
Plexium Inc |
Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.
|
|
EP4426305A1
(en)
|
2021-11-04 |
2024-09-11 |
F. Hoffmann-La Roche AG |
Novel use of quinazolinone compound for the treatment of cancer
|
|
WO2023084489A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
JP2025517430A
(ja)
|
2022-05-20 |
2025-06-05 |
ノバルティス アーゲー |
Ｅｐｈａ２ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法
|
|
EP4525926A1
(en)
|
2022-05-20 |
2025-03-26 |
Novartis AG |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
EP4536226A1
(en)
*
|
2022-06-06 |
2025-04-16 |
Alivus Life Sciences Limited |
Process for preparation of selumetinib and salts thereof
|
|
CN120265291A
(zh)
|
2022-11-18 |
2025-07-04 |
豪夫迈·罗氏有限公司 |
喹唑啉酮化合物的新用途和制剂
|
|
CN120752058A
(zh)
|
2023-03-10 |
2025-10-03 |
诺华股份有限公司 |
panRAS抑制剂抗体-药物缀合物及其使用方法
|
|
CN120813358A
(zh)
|
2023-04-06 |
2025-10-17 |
卫材R&D管理有限公司 |
用于治疗肿瘤的药物组合物
|
|
TWI905527B
(zh)
|
2023-06-01 |
2025-11-21 |
中化合成生技股份有限公司 |
6-(4-溴-2-氯-苯基胺基)-7-氟-3-甲基-3h-苯并咪唑-5-羧酸(2-乙烯基氧基-乙氧基)-醯胺硫酸鹽晶型ａ、ｂ、ｃ、ｄ、ｅ、ｆ及ｇ及其製造方法
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
PY24103486A
(es)
|
2023-11-22 |
2025-06-06 |
Servier Lab |
Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
|
|
FR3159741A1
(fr)
|
2024-03-04 |
2025-09-05 |
Pierre Fabre Medicament |
Formulation topique comprenant du binimetinib
|
|
TW202539634A
(zh)
|
2024-04-10 |
2025-10-16 |
瑞士商諾華公司 |
Ｐａｎｒａｓ抑制劑及其使用方法
|
|
PL249152B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249151B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL248506B1
(pl)
*
|
2025-01-27 |
2025-12-22 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249148B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249150B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249149B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|